Parexel Aims to Strengthen Clinical Research Capabilities in India with Continued Expansion Plans in Chandigarh and Mohali

Chandigarh, April 27, 2023: Leading provider of clinical research services, Parexel, announced plans to expand its operations in Chandigarh and Mohali, India, with the goal of strengthening its clinical research safety and design capability by 2025. The company aims to increase its current staff of 2,600 employees to 3,000+ over the next three years, with a focus on hiring statisticians, safety experts, pharmacovigilance professionals, and medical writers.

Parexel has a strong presence in Chandigarh, with experienced teams of clinical research professionals and pharmacovigilance experts. Chandigarh serves as a hub for academic institutions, research centers, and pharmaceutical companies, making it an ideal location for clinical research services. The city also boasts a large pool of experienced and well-trained medical professionals, as well as a diverse patient population, which is crucial for conducting successful clinical trials. This allows Parexel to provide high-quality services to global and regional clients.

Sanjay Vyas, EVP & Country Head India, Parexel highlighted the organization's partnership with Chitkara University, saying, "The clinical research industry has seen a tremendous boost owing to the patent expiration of branded drugs and further investments in new drug developments. Our goal with the 2-year Master's degree program in Pharmacovigilance & Clinical research was to design a program that creates skilled and competent professionals who can work effectively at different levels in Pharmacovigilance departments of leading Pharma companies and Clinical Research Organizations (CROs) in India as well as around the world.”

Students graduating from this program can find employment as Pharmacovigilance Scientists, Pharmacovigilance Quality Reviewers, Pharmacovigilance Quality Analysts, Pharmacovigilance Medical Safety Writers, Pharmacovigilance System Specialists, and more.

In addition to Chitkara University, Parexel also actively engages with Panjab University, having hired around 200-300 students from the institute over the past few years. Parexel provides industry and curriculum support as part of these collaborations.

India has become a popular destination for clinical trials due to its large patient population, diverse genetic pool, and skilled professionals. The clinical trials market is expected to increase at a CAGR of 8.2% from 2022 to 2030. In recent years, the Indian government has taken steps to streamline the regulatory process for clinical trials, making it easier for companies to conduct research in the country.

Parexel's expansion in Chandigarh and Mohali will contribute to the growth of India's clinical trials market and provide opportunities for skilled professionals. The company's commitment to patient-centricity and high-quality services will ensure the success of its clinical trials and benefit patients worldwide.